WCG to Feature Site‐Specific Solutions at ACRP 2019
Company to highlight expanded focus on investigative sites at Annual Meeting of the Association of Clinical Research Professionals (ACRP)
Princeton, NJ – April 10, 2019 – The WIRB-Copernicus Group’s® (WCG™) Site Division is pleased to announce its participation in the Annual Meeting of the Association of Clinical Research Professionals (ACRP) on April 12-15, 2019 in Nashville, TN. At ACRP 2019, WCG will feature SiteReady™, the company’s newest offering, which helps researchers to optimize their performance, gain a competitive edge, and attract more opportunities for income-generating clinical trials. WCG will also provide interested attendees with information about joining its Global Research Network™ (GRN) of investigative sites.
“We are pleased to support ACRP in its mission to improve clinical trial quality,” said Donald A. Deieso, PhD, Executive Chairman and CEO, WCG. “We look forward to learning from our colleagues and sharing new solutions and best practices with these vital members of the research community.”
Dr. Deieso is a featured speaker in ACRP’s ‘Signature Series’ Spotlight. He will join Virginia Nido, MSEd, Global Head, Product Development Industry Collaborations, Genentech; Andy Lee, SVP, Head of Global Clinical Trial Operations, Merck; and Jim Kremidas, Executive Director, ACRP, in a discussion regarding the evolution of roles supporting clinical trials and how new advances in operationalizing technology, data, and workflow processes will require new skills and competencies. The panel discussion, entitled, “Evolution of the Clinical Research Workforce for the Future,” will take place on Saturday, April 13th from 8:00-9:00AM.
WCG has also sponsored a Learning Lab, which is aimed at helping institutional representatives to operationalize the NIH single IRB mandate based on Yale University’s approach. The presentation will address the mechanics of getting budgets and making decisions, systemizing follow up, securing just-in-time funding, and conducting initial review. Presenters include Stuart Horowitz, PhD, WCG’s President of Institutions and Institutional Services, Linda M. Coleman, JD, CIP, CHC, CHRC, CCEP-I of Yale University and Madeleine Williams, MA of Huron Consulting Group. The session is titled, “Operationalizing the Single IRB Mandate: The Yale University Approach,” and will take place on Sunday, April 14th from 12:30 – 1:00PM.
“We are privileged to support clinical research sites in their critically important work of conducting clinical trials,” said Jonathan Zung, PhD, Executive Vice President of WCG’s Site Division. “We are proud to offer them new solutions to increase the efficiency and profitability of clinical research, unparalleled data for peer-to-peer benchmarking and continuous improvement, and inclusion in our GRN —the premier network of sites available in the industry— to help them attract more industry-sponsored trials.”
Established in 2012, the GRN now includes over 2,800 of the leading research sites which participate in sponsor-funded clinical trials. Membership in WCG’s GRN provides members with a number of benefits including continuous education, advisory services, and relationship building with biopharma sponsors within targeted therapeutic areas. There are no fees or other financial requirements for membership – only the commitment to performing high-quality clinical trials. Interested parties should contact Sean Walsh, MBA, ACHE, President of Independent Sites at firstname.lastname@example.org for further information.
About WCG (WIRB-Copernicus Group)
WCG is the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research. The industry’s first clinical services organization (CSO), WCG enables biopharmaceutical companies, CROs, and institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining the highest standards of human subject protection. For more information, please visit www.wcgclinical.com or follow us on Twitter @WCGClinical or LinkedIn.